Ovarian Cancer Pipeline 2026: Drugs in Trials & Targets

Remission & chronicity

Spontaneous remission

No spontaneous remission; 5-year survival Stage I: 90%; Stage III/IV: 25-30%; most patients (75%) present at Stage III-IV

Best-intervention remission

Debulking surgery + carboplatin/paclitaxel: 70-80% initial response; PARP inhibitors (olaparib, rucaparib) maintenance in BRCA-mutant: 56% 5-year PFS vs 13.8% placebo (SOLO-1); bevacizumab maintenance: modest PFS benefit; dose-dense paclitaxel: 72.1% vs 65.1% OS at 3 years

Gap size

Large — PARP inhibitors dramatically improve outcomes in BRCA-mutant patients; HRD testing not universal; no effective screening exists

Primary barrier

access + biological

BRCA1/2 and HRD testing is not universal despite major impact on PARP inhibitor eligibility; bevacizumab access limited by cost; most patients are diagnosed at advanced stage due to no screening modality; CA-125 + transvaginal ultrasound screening trials (UKCTOCS) failed to show mortality reduction

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

BRCA1 283 BRCA2 19 CCNE1 15 FOLR1 80 KDR 382 MSLN 9 PARP1 207 PARP2 189 PIK3CA 444 SLC34A2 71 TP53 652 VEGFA 207

BRCA1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
7-HYDROXY ISOFLAVONE	? unclear	Mechanistic	DGIdb
OLAPARIB	? unclear	Mechanistic	DGIdb
PLATINUM COMPOUND	? unclear	Mechanistic	DGIdb
DAIDZIN	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL581929	? unclear	Mechanistic	DGIdb
PIDNARULEX	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL1481721	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL484663	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL1214407	? unclear	Mechanistic	DGIdb
2-PHENYLQUINOLINE	? unclear	Mechanistic	DGIdb
HARMALOL	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL1574420	? unclear	Mechanistic	DGIdb
DOXORUBICIN HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
MITOMYCIN	? unclear	Mechanistic	DGIdb
PACLITAXEL PROTEIN-BOUND	? unclear	Mechanistic	DGIdb
RESVERATROL	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL12658	? unclear	Mechanistic	DGIdb
ONONIN	? unclear	Mechanistic	DGIdb
CEDIRANIB	? unclear	Mechanistic	DGIdb
PIPERINE	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL446567	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL546649	? unclear	Mechanistic	DGIdb
DEPHOSTATIN	? unclear	Mechanistic	DGIdb
SEMUSTINE	? unclear	Mechanistic	DGIdb
CISPLATIN	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL1404865	? unclear	Mechanistic	DGIdb
QUARFLOXIN	? unclear	Mechanistic	DGIdb
PARP/TANKYRASE INHIBITOR 2X-121	? unclear	Mechanistic	DGIdb
WISTIN	? unclear	Mechanistic	DGIdb
CHRYSIN DIMETHYL ETHER	? unclear	Mechanistic	DGIdb
GEMCITABINE	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL600315	? unclear	Mechanistic	DGIdb
AURINTRICARBOXYLIC ACID	? unclear	Mechanistic	DGIdb
MITOXANTRONE HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
SACITUZUMAB GOVITECAN	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL588683	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL593254	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL588525	? unclear	Mechanistic	DGIdb
PURPURIN	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL316796	? unclear	Mechanistic	DGIdb

Showing top 40 of 283 agents ranked by evidence tier.

BRCA2

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
CARBOPLATIN	? unclear	Mechanistic	DGIdb
OLAPARIB	? unclear	Mechanistic	DGIdb
TALAZOPARIB	? unclear	Mechanistic	DGIdb
NIRAPARIB	? unclear	Mechanistic	DGIdb
RUCAPARIB	? unclear	Mechanistic	DGIdb
QUARFLOXIN	? unclear	Mechanistic	DGIdb
CISPLATIN	? unclear	Mechanistic	DGIdb
VELIPARIB	? unclear	Mechanistic	DGIdb
BOSUTINIB	? unclear	Mechanistic	DGIdb
PLATINUM COMPOUND	? unclear	Mechanistic	DGIdb
TEMOZOLOMIDE	? unclear	Mechanistic	DGIdb
ENZALUTAMIDE	? unclear	Mechanistic	DGIdb
DASATINIB ANHYDROUS	? unclear	Mechanistic	DGIdb
GEMCITABINE	? unclear	Mechanistic	DGIdb
PIDNARULEX	? unclear	Mechanistic	DGIdb
SACITUZUMAB GOVITECAN	? unclear	Mechanistic	DGIdb
CEDIRANIB	? unclear	Mechanistic	DGIdb
INIPARIB	? unclear	Mechanistic	DGIdb
PARP/TANKYRASE INHIBITOR 2X-121	? unclear	Mechanistic	DGIdb

CCNE1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
TASELISIB	? unclear	Mechanistic		DGIdb
CAMONSERTIB	? unclear	Mechanistic		DGIdb
FULVESTRANT	? unclear	Mechanistic		DGIdb
ALISERTIB	? unclear	Mechanistic		DGIdb
AMG-900	? unclear	Mechanistic		DGIdb
DINACICLIB	? unclear	Mechanistic		DGIdb
LUNRESERTIB	? unclear	Mechanistic		DGIdb
CDK INHIBITOR SNS-032	? unclear	Mechanistic		DGIdb
FADRACICLIB	? unclear	Mechanistic		DGIdb
RONICICLIB	? unclear	Mechanistic		DGIdb
PALBOCICLIB	? unclear	Mechanistic		DGIdb
AKT INHIBITOR MK2206	? unclear	Mechanistic		DGIdb
AZD-5438	↓ inhibits	Mechanistic	6.0 nM (IC50)	ChEMBL
CHEMBL5653589	↓ inhibits	Mechanistic	14.99 nM (Kd)	ChEMBL
CHEMBL3752910	↓ inhibits	Mechanistic	74.76 nM (Kd)	ChEMBL

FOLR1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
MIRVETUXIMAB SORAVTANSINE	? unclear	Mechanistic		DGIdb
VINTAFOLIDE	~ modulates	Mechanistic		DGIdb
MIRVETUXIMAB	~ modulates	Mechanistic		DGIdb
FARLETUZUMAB	? unclear	Mechanistic		DGIdb
RINATABART SESUTECAN	? unclear	Mechanistic		DGIdb
FOLATE RECEPTOR-TARGETED VINCA ALKALOID EC0489	? unclear	Mechanistic		DGIdb
EPOFOLATE	? unclear	Mechanistic		DGIdb
PYRIMETHAMINE	? unclear	Mechanistic		DGIdb
FOLIC ACID	? unclear	Mechanistic		DGIdb
TALOTREXIN	? unclear	Mechanistic		DGIdb
ANTIESTROGEN	? unclear	Mechanistic		DGIdb
LOMETREXOL	? unclear	Mechanistic		DGIdb
DEXAMETHASONE	? unclear	Mechanistic		DGIdb
METHOTREXATE	? unclear	Mechanistic	461.0 nM (IC50)	DGIdb
TETRAHYDROFOLIC ACID	? unclear	Mechanistic		DGIdb
CHEMBL85871	↓ inhibits	Mechanistic	0.153 nM (Kd)	ChEMBL
CHEMBL315627	↓ inhibits	Mechanistic	136.0 nM (Kd)	ChEMBL
CHEMBL85848	↓ inhibits	Mechanistic	83.0 nM (Kd)	ChEMBL
CHEMBL82390	↓ inhibits	Mechanistic	0.69 nM (Kd)	ChEMBL
CHEMBL309415	↓ inhibits	Mechanistic	0.57 nM (Kd)	ChEMBL
CHEMBL84935	↓ inhibits	Mechanistic	0.38 nM (Kd)	ChEMBL
CHEMBL82261	↓ inhibits	Mechanistic	0.95 nM (Kd)	ChEMBL
PEMETREXED	↓ inhibits	Mechanistic	388.0 nM (IC50)	ChEMBL
RALTITREXED	↓ inhibits	Mechanistic	15.0 nM (IC50)	ChEMBL
CHEMBL3335607	↓ inhibits	Mechanistic	55.7 nM (IC50)	ChEMBL
CHEMBL3335606	↓ inhibits	Mechanistic	27.4 nM (IC50)	ChEMBL
CHEMBL3335605	↓ inhibits	Mechanistic	9.5 nM (IC50)	ChEMBL
CHEMBL3335604	↓ inhibits	Mechanistic	6.6 nM (IC50)	ChEMBL
CHEMBL3335603	↓ inhibits	Mechanistic	661.0 nM (IC50)	ChEMBL
CHEMBL1834488	↓ inhibits	Mechanistic	0.31 nM (IC50)	ChEMBL
CHEMBL590740	↓ inhibits	Mechanistic	1.82 nM (IC50)	ChEMBL
CHEMBL3407519	↓ inhibits	Mechanistic	550.0 nM (IC50)	ChEMBL
CHEMBL3409334	↓ inhibits	Mechanistic	109.0 nM (IC50)	ChEMBL
CHEMBL3409335	↓ inhibits	Mechanistic	49.3 nM (IC50)	ChEMBL
CHEMBL3409336	↓ inhibits	Mechanistic	45.5 nM (IC50)	ChEMBL
CHEMBL3628344	↓ inhibits	Mechanistic	0.33 nM (IC50)	ChEMBL
CHEMBL3628345	↓ inhibits	Mechanistic	154.0 nM (IC50)	ChEMBL
CHEMBL3628346	↓ inhibits	Mechanistic	0.61 nM (IC50)	ChEMBL
CHEMBL3628347	↓ inhibits	Mechanistic	148.0 nM (IC50)	ChEMBL
CHEMBL365307	↓ inhibits	Mechanistic	6.3 nM (IC50)	ChEMBL

Showing top 40 of 80 agents ranked by evidence tier.

KDR

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
CEDIRANIB	↓ inhibits	Mechanistic		DGIdb
XL820	↓ inhibits	Mechanistic		DGIdb
EUPATORIN	↓ inhibits	Mechanistic		DGIdb
CABOZANTINIB S-MALATE	↓ inhibits	Mechanistic		DGIdb
TOCERANIB	↓ inhibits	Mechanistic		DGIdb
LAZERTINIB	↓ inhibits	Mechanistic		DGIdb
VADIMEZAN	? unclear	Mechanistic		DGIdb
VANDETANIB	↓ inhibits	Mechanistic	70.0 nM (IC50)	DGIdb
SURUFATINIB	↓ inhibits	Mechanistic		DGIdb
CANLITINIB	↓ inhibits	Mechanistic		DGIdb
FORETINIB	↓ inhibits	Mechanistic		DGIdb
PEGPLERANIB SODIUM	? unclear	Mechanistic		DGIdb
REGORAFENIB	↓ inhibits	Mechanistic		DGIdb
LINIFANIB	↓ inhibits	Mechanistic		DGIdb
MOTESANIB	↓ inhibits	Mechanistic		DGIdb
ILORASERTIB	↓ inhibits	Mechanistic		DGIdb
SUNITINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 13A [PMID: 23639540]	↓ inhibits	Mechanistic		DGIdb
PONATINIB	↓ inhibits	Mechanistic		DGIdb
XL-820	↓ inhibits	Mechanistic		DGIdb
BX-795	↓ inhibits	Mechanistic		DGIdb
TELATINIB	↓ inhibits	Mechanistic		DGIdb
SORAFENIB	↓ inhibits	Mechanistic		DGIdb
LUCITANIB	↓ inhibits	Mechanistic		DGIdb
PP-121	↓ inhibits	Mechanistic		DGIdb
NINGETINIB	↓ inhibits	Mechanistic		DGIdb
TINENGOTINIB	↓ inhibits	Mechanistic		DGIdb
BJ-2412	↓ inhibits	Mechanistic		DGIdb
VEGF RECEPTOR TYROSINE KINASE INHIBITOR III	↓ inhibits	Mechanistic		DGIdb
PF-00337210	↓ inhibits	Mechanistic		DGIdb
AST-487	↓ inhibits	Mechanistic		DGIdb
RAMUCIRUMAB	↓ inhibits	Mechanistic		DGIdb
AG-13958	↓ inhibits	Mechanistic		DGIdb
SU-14813	↓ inhibits	Mechanistic		DGIdb
X-82	↓ inhibits	Mechanistic		DGIdb
ENMD-2076	↓ inhibits	Mechanistic		DGIdb
GOLVATINIB	↓ inhibits	Mechanistic		DGIdb
CENISERTIB	? unclear	Mechanistic		DGIdb
LENVATINIB	↓ inhibits	Mechanistic		DGIdb
SULFATINIB	↓ inhibits	Mechanistic		DGIdb

Showing top 40 of 382 agents ranked by evidence tier.

MSLN

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
AMATUXIMAB	? unclear	Mechanistic	DGIdb
CRS-207	? unclear	Mechanistic	DGIdb
SS1(DSFV)-PE38	? unclear	Mechanistic	DGIdb
ANETUMAB RAVTANSINE	~ modulates	Mechanistic	DGIdb
ANTI-MUC16/MMAE ANTIBODY-DRUG CONJUGATE DMUC4064A	? unclear	Mechanistic	DGIdb
LMB-100	~ modulates	Mechanistic	DGIdb
AUTOLOGOUS MESOTHELIN-SPECIFIC CAR-T CELLS	? unclear	Mechanistic	DGIdb
ANTI-MESOTHELIN CAR T CELLS PREPARATION	? unclear	Mechanistic	DGIdb
RG-7600	~ modulates	Mechanistic	DGIdb

PARP1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
NIRAPARIB	↓ inhibits	Mechanistic	DGIdb
VELIPARIB	↓ inhibits	Mechanistic	DGIdb
4-[3-(1,4-DIAZEPAN-1-YLCARBONYL)-4-FLUOROBENZYL]PHTHALAZIN-1(2H)-ONE	↓ inhibits	Mechanistic	DGIdb
PAMIPARIB	↓ inhibits	Mechanistic	DGIdb
OLAPARIB	↓ inhibits	Mechanistic	DGIdb
COMPOUND 5 [TOMASSI ET AL., 2020]	↓ inhibits	Mechanistic	DGIdb
COMPOUND 9 [LIN ET AL., 2023]	↓ inhibits	Mechanistic	DGIdb
INIPARIB	↓ inhibits	Mechanistic	DGIdb
AZ1366	↓ inhibits	Mechanistic	DGIdb
DUAL VEGFR/PARP INHIBITOR 14B	↓ inhibits	Mechanistic	DGIdb
NIACIN	? unclear	Mechanistic	DGIdb
2X-121	↓ inhibits	Mechanistic	DGIdb
AMELPARIB DIHYDROCHLORIDE DIHYDRATE	↓ inhibits	Mechanistic	DGIdb
CEP-9722	? unclear	Mechanistic	DGIdb
ORAL AZACITIDINE	? unclear	Mechanistic	DGIdb
RUCAPARIB PHOSPHATE	↓ inhibits	Mechanistic	DGIdb
AG14361	↓ inhibits	Mechanistic	DGIdb
ME0328	↓ inhibits	Mechanistic	DGIdb
SARUPARIB	↓ inhibits	Mechanistic	DGIdb
SENAPARIB	↓ inhibits	Mechanistic	DGIdb
NIRAPARIB TOSYLATE	? unclear	Mechanistic	DGIdb
TALAZOPARIB	↓ inhibits	Mechanistic	DGIdb
PJ34	↓ inhibits	Mechanistic	DGIdb
TALAZOPARIB TOSYLATE	↓ inhibits	Mechanistic	DGIdb
PARP1 INHIBITOR (S)-G9	↓ inhibits	Mechanistic	DGIdb
NICARAVEN	? unclear	Mechanistic	DGIdb
PARP-1/2 INHIBITOR ABT-767	? unclear	Mechanistic	DGIdb
INO-1001	? unclear	Mechanistic	DGIdb
BGP-15	? unclear	Mechanistic	DGIdb
RUCAPARIB	↓ inhibits	Mechanistic	DGIdb
TRABECTEDIN	? unclear	Mechanistic	DGIdb
VENADAPARIB	↓ inhibits	Mechanistic	DGIdb
FLUZOPARIB	↓ inhibits	Mechanistic	DGIdb
MC2050	↓ inhibits	Mechanistic	DGIdb
PARP INHIBITOR E7016	? unclear	Mechanistic	DGIdb
LERZEPARIB	↓ inhibits	Mechanistic	DGIdb
CICLOPIROX	↓ inhibits	Mechanistic	DGIdb
E-7016	↓ inhibits	Mechanistic	DGIdb
RUCAPARIB CAMSYLATE	↓ inhibits	Mechanistic	DGIdb
PALACAPARIB	↓ inhibits	Mechanistic	DGIdb

Showing top 40 of 207 agents ranked by evidence tier.

PARP2

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
RUCAPARIB	↓ inhibits	Mechanistic		DGIdb
TALAZOPARIB	↓ inhibits	Mechanistic	0.85 nM (Ki)	DGIdb
PALACAPARIB	↓ inhibits	Mechanistic		DGIdb
E-7016	↓ inhibits	Mechanistic		DGIdb
SARUPARIB	↓ inhibits	Mechanistic		DGIdb
NIRAPARIB	↓ inhibits	Mechanistic	2.1 nM (IC50)	DGIdb
PAMIPARIB	↓ inhibits	Mechanistic	0.5 nM (IC50)	DGIdb
2X-121	↓ inhibits	Mechanistic		DGIdb
AZ1366	↓ inhibits	Mechanistic		DGIdb
COMPOUND 5 [TOMASSI ET AL., 2020]	↓ inhibits	Mechanistic		DGIdb
SENAPARIB	↓ inhibits	Mechanistic		DGIdb
TALAZOPARIB TOSYLATE	↓ inhibits	Mechanistic		DGIdb
PARP1 INHIBITOR (S)-G9	↓ inhibits	Mechanistic		DGIdb
MC2050	↓ inhibits	Mechanistic		DGIdb
COMPOUND 10B [PMID: 26222319]	↓ inhibits	Mechanistic		DGIdb
NIRAPARIB TOSYLATE MONOHYDRATE	↓ inhibits	Mechanistic		DGIdb
OLAPARIB	↓ inhibits	Mechanistic	1.0 nM (IC50)	DGIdb
RUCAPARIB CAMSYLATE	↓ inhibits	Mechanistic		DGIdb
VELIPARIB	↓ inhibits	Mechanistic	5.0 nM (Ki)	DGIdb
CHEMBL527654	↓ inhibits	Mechanistic	11.0 nM (Ki)	ChEMBL
CHEMBL497608	↓ inhibits	Mechanistic	2.0 nM (Ki)	ChEMBL
CHEMBL526668	↓ inhibits	Mechanistic	2.0 nM (Ki)	ChEMBL
CHEMBL495743	↓ inhibits	Mechanistic	4.0 nM (Ki)	ChEMBL
CHEMBL495942	↓ inhibits	Mechanistic	2.0 nM (Ki)	ChEMBL
CHEMBL518484	↓ inhibits	Mechanistic	24.0 nM (Ki)	ChEMBL
CHEMBL460267	↓ inhibits	Mechanistic	3.0 nM (Ki)	ChEMBL
CHEMBL452801	↓ inhibits	Mechanistic	2.0 nM (Ki)	ChEMBL
CHEMBL452800	↓ inhibits	Mechanistic	5.0 nM (Ki)	ChEMBL
CHEMBL558845	↓ inhibits	Mechanistic	32.0 nM (IC50)	ChEMBL
CHEMBL560790	↓ inhibits	Mechanistic	17.0 nM (IC50)	ChEMBL
CHEMBL595018	↓ inhibits	Mechanistic	1.0 nM (IC50)	ChEMBL
CHEMBL609002	↓ inhibits	Mechanistic	1.0 nM (IC50)	ChEMBL
CHEMBL1089125	↓ inhibits	Mechanistic	4.0 nM (Ki)	ChEMBL
CHEMBL1093309	↓ inhibits	Mechanistic	3.0 nM (Ki)	ChEMBL
CHEMBL1092223	↓ inhibits	Mechanistic	23.0 nM (Ki)	ChEMBL
CHEMBL1089474	↓ inhibits	Mechanistic	26.0 nM (Ki)	ChEMBL
CHEMBL1093012	↓ inhibits	Mechanistic	12.0 nM (Ki)	ChEMBL
CHEMBL1090483	↓ inhibits	Mechanistic	10.0 nM (Ki)	ChEMBL
CHEMBL1090482	↓ inhibits	Mechanistic	18.0 nM (Ki)	ChEMBL
CHEMBL1090136	↓ inhibits	Mechanistic	1.0 nM (Ki)	ChEMBL

Showing top 40 of 189 agents ranked by evidence tier.

PIK3CA

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
SURAMIN	? unclear	Mechanistic		DGIdb
TEMSIROLIMUS	? unclear	Mechanistic		DGIdb
RIGOSERTIB	↓ inhibits	Mechanistic		DGIdb
NEOLYMPHOSTIN A	↓ inhibits	Mechanistic		DGIdb
INAVOLISIB	↓ inhibits	Mechanistic		DGIdb
RIGOSERTIB SODIUM	? unclear	Mechanistic		DGIdb
TAK-733	? unclear	Mechanistic		DGIdb
APILIMOD DIMESYLATE CAPSULE	? unclear	Mechanistic		DGIdb
COMPOUND 15A [PMID: 32069401]	↓ inhibits	Mechanistic		DGIdb
COMPOUND 41 [PMID: 31855425]	↓ inhibits	Mechanistic		DGIdb
ERDAFITINIB	? unclear	Mechanistic		DGIdb
RIBOCICLIB	? unclear	Mechanistic		DGIdb
BRAFV600/PI3K INHIBITOR ASN003	? unclear	Mechanistic		DGIdb
GSK2636771	↓ inhibits	Mechanistic		DGIdb
ZINC SULFATE ANHYDROUS	? unclear	Mechanistic		DGIdb
EVEROLIMUS	? unclear	Mechanistic		DGIdb
COPANLISIB	↓ inhibits	Mechanistic		DGIdb
TANESPIMYCIN	? unclear	Mechanistic		DGIdb
CAPIVASERTIB	? unclear	Mechanistic		DGIdb
SAMOTOLISIB	↓ inhibits	Mechanistic		DGIdb
COPANLISIB HYDROCHLORIDE	↓ inhibits	Mechanistic		DGIdb
PAXALISIB	↓ inhibits	Mechanistic		DGIdb
U0126	? unclear	Mechanistic		DGIdb
PILARALISIB	↓ inhibits	Mechanistic		DGIdb
M-2698	? unclear	Mechanistic		DGIdb
GSK2334470	? unclear	Mechanistic		DGIdb
BIMIRALISIB	↓ inhibits	Mechanistic		DGIdb
PALBOCICLIB	? unclear	Mechanistic		DGIdb
SONOLISIB	↓ inhibits	Mechanistic	88.0 nM (IC50)	DGIdb
VULOLISIB	↓ inhibits	Mechanistic		DGIdb
ALPELISIB	↓ inhibits	Mechanistic		DGIdb
DOCETAXEL ANHYDROUS	? unclear	Mechanistic		DGIdb
COMPOUND 27 [PMID: 35834807]	↓ inhibits	Mechanistic		DGIdb
MILTEFOSINE	? unclear	Mechanistic		DGIdb
CARBOPLATIN	? unclear	Mechanistic		DGIdb
ACALISIB	↓ inhibits	Mechanistic		DGIdb
GEDATOLISIB	↓ inhibits	Mechanistic		DGIdb
VS-5584	↓ inhibits	Mechanistic		DGIdb
XRD-0394	↓ inhibits	Mechanistic		DGIdb
IZORLISIB	? unclear	Mechanistic		DGIdb

Showing top 40 of 444 agents ranked by evidence tier.

SLC34A2

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
LIFASTUZUMAB VEDOTIN	~ modulates	Mechanistic		DGIdb
COMPOUND 15 [PMID: 35034442]	↓ inhibits	Mechanistic		DGIdb
CHEMBL4159390	↓ inhibits	Mechanistic	150.0 nM (IC50)	ChEMBL
CHEMBL5174202	↓ inhibits	Mechanistic	120.0 nM (IC50)	ChEMBL
CHEMBL5182987	↓ inhibits	Mechanistic	15.0 nM (IC50)	ChEMBL
CHEMBL5171732	↓ inhibits	Mechanistic	64.0 nM (IC50)	ChEMBL
CHEMBL5169559	↓ inhibits	Mechanistic	2881.0 nM (IC50)	ChEMBL
CHEMBL5180542	↓ inhibits	Mechanistic	1404.0 nM (IC50)	ChEMBL
CHEMBL5180294	↓ inhibits	Mechanistic	1140.0 nM (IC50)	ChEMBL
CHEMBL5206581	↓ inhibits	Mechanistic	71.0 nM (IC50)	ChEMBL
CHEMBL5188788	↓ inhibits	Mechanistic	288.0 nM (IC50)	ChEMBL
CHEMBL5188991	↓ inhibits	Mechanistic	43.0 nM (IC50)	ChEMBL
CHEMBL5172080	↓ inhibits	Mechanistic	103.0 nM (IC50)	ChEMBL
CHEMBL5175794	↓ inhibits	Mechanistic	24.0 nM (IC50)	ChEMBL
CHEMBL5173115	↓ inhibits	Mechanistic	61.0 nM (IC50)	ChEMBL
CHEMBL5170356	↓ inhibits	Mechanistic	14.0 nM (IC50)	ChEMBL
CHEMBL5188295	↓ inhibits	Mechanistic	257.0 nM (IC50)	ChEMBL
CHEMBL5192917	↓ inhibits	Mechanistic	71.0 nM (IC50)	ChEMBL
CHEMBL5205024	↓ inhibits	Mechanistic	538.0 nM (IC50)	ChEMBL
CHEMBL5182681	↓ inhibits	Mechanistic	448.0 nM (IC50)	ChEMBL
CHEMBL5192454	↓ inhibits	Mechanistic	369.0 nM (IC50)	ChEMBL
CHEMBL5174538	↓ inhibits	Mechanistic	356.0 nM (IC50)	ChEMBL
CHEMBL5175718	↓ inhibits	Mechanistic	78.0 nM (IC50)	ChEMBL
CHEMBL5197471	↓ inhibits	Mechanistic	1015.0 nM (IC50)	ChEMBL
CHEMBL5197826	↓ inhibits	Mechanistic	2582.0 nM (IC50)	ChEMBL
CHEMBL5203825	↓ inhibits	Mechanistic	166.0 nM (IC50)	ChEMBL
CHEMBL5184710	↓ inhibits	Mechanistic	535.0 nM (IC50)	ChEMBL
CHEMBL5169500	↓ inhibits	Mechanistic	401.0 nM (IC50)	ChEMBL
CHEMBL5206879	↓ inhibits	Mechanistic	401.0 nM (IC50)	ChEMBL
CHEMBL5194589	↓ inhibits	Mechanistic	267.0 nM (IC50)	ChEMBL
CHEMBL5174544	↓ inhibits	Mechanistic	1000.0 nM (IC50)	ChEMBL
CHEMBL5185371	↓ inhibits	Mechanistic	118.0 nM (IC50)	ChEMBL
CHEMBL5204866	↓ inhibits	Mechanistic	437.0 nM (IC50)	ChEMBL
CHEMBL5206181	↓ inhibits	Mechanistic	713.0 nM (IC50)	ChEMBL
CHEMBL5178362	↓ inhibits	Mechanistic	2486.0 nM (IC50)	ChEMBL
CHEMBL5180710	↓ inhibits	Mechanistic	80.0 nM (IC50)	ChEMBL
CHEMBL5204879	↓ inhibits	Mechanistic	36.0 nM (IC50)	ChEMBL
CHEMBL5192822	↓ inhibits	Mechanistic	38.0 nM (IC50)	ChEMBL
CHEMBL5185161	↓ inhibits	Mechanistic	46.0 nM (IC50)	ChEMBL
CHEMBL5203134	↓ inhibits	Mechanistic	179.0 nM (IC50)	ChEMBL

Showing top 40 of 71 agents ranked by evidence tier.

TP53

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
PIRARUBICIN	? unclear	Mechanistic	DGIdb
OXALIPLATIN	? unclear	Mechanistic	DGIdb
SIREMADLIN	↓ inhibits	Mechanistic	DGIdb
CARBOPLATIN	? unclear	Mechanistic	DGIdb
DAUNORUBICIN HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL260560	? unclear	Mechanistic	DGIdb
MELPHALAN	? unclear	Mechanistic	DGIdb
LAPACHONE	? unclear	Mechanistic	DGIdb
VITAMIN K3	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL260451	? unclear	Mechanistic	DGIdb
DINOSEB	? unclear	Mechanistic	DGIdb
RIMCAZOLE	? unclear	Mechanistic	DGIdb
TRACAZOLATE	? unclear	Mechanistic	DGIdb
CAPIVASERTIB	? unclear	Mechanistic	DGIdb
AZD7648	? unclear	Mechanistic	DGIdb
QUINALIZARIN	? unclear	Mechanistic	DGIdb
INOSITOL	? unclear	Mechanistic	DGIdb
ECONAZOLE NITRATE	? unclear	Mechanistic	DGIdb
L-733,060	? unclear	Mechanistic	DGIdb
U50488	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL260028	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL601140	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL408563	? unclear	Mechanistic	DGIdb
ENALAPRIL MALEATE	? unclear	Mechanistic	DGIdb
HOMIDIUM BROMIDE	? unclear	Mechanistic	DGIdb
IOXYNIL	? unclear	Mechanistic	DGIdb
ACALABRUTINIB	? unclear	Mechanistic	DGIdb
INDOPROFEN	? unclear	Mechanistic	DGIdb
MERCAPTOPURINE	? unclear	Mechanistic	DGIdb
AUTOLOGOUS DENDRITIC CELLS TRANSDUCED WITH WILD-TYPE P53 ADENOVIRUS VACCINE	? unclear	Mechanistic	DGIdb
ZIRAM	? unclear	Mechanistic	DGIdb
IFOSFAMIDE	? unclear	Mechanistic	DGIdb
DOCETAXEL ANHYDROUS	? unclear	Mechanistic	DGIdb
SOTULETINIB	? unclear	Mechanistic	DGIdb
SERTRALINE HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
PD166285	? unclear	Mechanistic	DGIdb
SAPANISERTIB	? unclear	Mechanistic	DGIdb
ENZALUTAMIDE	? unclear	Mechanistic	DGIdb
PYRITHIONE ZINC	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL1169388	? unclear	Mechanistic	DGIdb

Showing top 40 of 652 agents ranked by evidence tier.

VEGFA

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
BEVASIRANIB	? unclear	Mechanistic	DGIdb
RANIBIZUMAB	↓ inhibits	Mechanistic	DGIdb
CP-547632	? unclear	Mechanistic	DGIdb
EW-A-401	? unclear	Mechanistic	DGIdb
BEVACIZUMAB 111IN	~ modulates	Mechanistic	DGIdb
FENOFIBRATE MICRONIZED	? unclear	Mechanistic	DGIdb
PEGAPTANIB	↓ inhibits	Mechanistic	DGIdb
DEXAMETHASONE	? unclear	Mechanistic	DGIdb
SQUALAMINE	? unclear	Mechanistic	DGIdb
AFLIBERCEPT	↓ inhibits	Mechanistic	DGIdb
PAZOPANIB	? unclear	Mechanistic	DGIdb
BEVACIZUMAB GAMMA	~ modulates	Mechanistic	DGIdb
CILOSTAZOL	? unclear	Mechanistic	DGIdb
ADALIMUMAB	? unclear	Mechanistic	DGIdb
MUPARFOSTAT	↓ inhibits	Mechanistic	DGIdb
SILDENAFIL	? unclear	Mechanistic	DGIdb
PENTOSAN POLYSULFATE	? unclear	Mechanistic	DGIdb
THALIDOMIDE	? unclear	Mechanistic	DGIdb
RISUTEGANIB	? unclear	Mechanistic	DGIdb
SELECTIVE CYTOKINE INHIBITORY DRUG CC-1088	? unclear	Mechanistic	DGIdb
PHENETHYL ISOTHIOCYANATE	? unclear	Mechanistic	DGIdb
EMVODODSTAT	? unclear	Mechanistic	DGIdb
CARFILZOMIB	? unclear	Mechanistic	DGIdb
FARICIMAB	↓ inhibits	Mechanistic	DGIdb
ALBUTEROL SULFATE	? unclear	Mechanistic	DGIdb
LENALIDOMIDE	↓ inhibits	Mechanistic	DGIdb
SUNITINIB	? unclear	Mechanistic	DGIdb
SHARK CARTILAGE EXTRACT AE-941	? unclear	Mechanistic	DGIdb
NM-3	? unclear	Mechanistic	DGIdb
DILPACIMAB	? unclear	Mechanistic	DGIdb
PEMETREXED DISODIUM	? unclear	Mechanistic	DGIdb
BI-836880	? unclear	Mechanistic	DGIdb
BROLUCIZUMAB	↓ inhibits	Mechanistic	DGIdb
DOMATINOSTAT	? unclear	Mechanistic	DGIdb
ANTHRACYCLINE ANTINEOPLASTIC ANTIBIOTIC	? unclear	Mechanistic	DGIdb
VEGF/HGF-TARGETING DARPIN MP0250	? unclear	Mechanistic	DGIdb
WARFARIN	? unclear	Mechanistic	DGIdb
CELECOXIB	? unclear	Mechanistic	DGIdb
NAVICIXIZUMAB	? unclear	Mechanistic	DGIdb
VEGLIN	? unclear	Mechanistic	DGIdb

Showing top 40 of 207 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Ovarian Cancer: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer Recruiting

NCT06542549 Phase: 3 Started: 2025-03-11

This is a randomized, controlled, multicenter clinical study to evaluate AK104 in FIGO 2018 stage III-IV ovarian cancer subjects who were assessed to be at high perioperative risk and/or unable to achieve R0 resection prior to initial treatment. The efficacy and safety of neoadjuvant therapy with in...

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) Recruiting

NCT06819007 Phase: 3 Started: 2025-03-19

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-...

BEACON - ABC in Recurrent Platinum Resistant HGSOC Completed

NCT03363867 Phase: 2 Started: 2018-07-10

Epithelial ovarian cancer (EOC) is the ninth most common cause of cancer in Australian women, with an estimated 1500 new diagnoses in Australia in 2015, and remains the seventh most common cause of cancer death in Australian women. High grade serous ovarian cancer (HGSC) is the most common form of E...

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer Recruiting

NCT06394804 Phase: 2 Started: 2024-04-29

The researchers are doing this study to find out whether the combination of avutometinib, defactinib, and letrozole is an effective treatment for people with low-grade serous ovarian cancer (LGSOC). The researchers will also look at the safety of this combination.

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy Recruiting

NCT05460000 Phase: 2 Started: 2024-10-11

Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass following primary tumor debulking to determine recurrence free survival...

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer Recruiting

NCT07489287 Phase: 1 Started: 2026-08-18

This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.

A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. Recruiting

NCT07778498 Phase: 1/2 Started: 2026-09-29

The goal of this clinical trial is to evaluate whether TJ102, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced ovarian or other solid tumors. The main objectives of this study are : • To Determine the maximum tolerated dose (MTD) and recommend...

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) Recruiting

NCT07776691 Phase: 3 Started: 2026-09-18

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: Maintenance treatment, which is used ...

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). Recruiting

NCT06843447 Phase: 1/2 Started: 2025-04-15

Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (...

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. Recruiting

NCT06890338 Phase: 2 Started: 2025-11-21

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous e...

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian Completed

NCT04374630 Phase: 2 Started: 2020-07-07

Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression. Afuresertib plus chemotherapy has demonstrated anti-tumor efficacy and an acceptable safety profile in pati...

A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine Recruiting

NCT03854110 Phase: 1 Started: 2019-01-14

This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2 of the study. Part 1 of the study evaluating misetionamide in combination with gemcitabine in subjects with advanced pan...

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) Recruiting

NCT07743164 Phase: 3 Started: 2026-10-07

Researchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery. High-grade means the cancer cells grow and spread quickly. This trial includes types of OC that st...

Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting

NCT07665515 Phase: 1 Started: 2026-09

Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer. The most common and aggressive form is called high-grade serous ovarian cancer. The main purpose of this study is to understand whether an experimen...

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Recruiting

NCT07816666 Phase: 3 Started: 2026-09-24

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)

Agents Found By Disease-Level Search

Searched directly from “Ovarian Cancer” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 12-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

47 agents shown (approved or with trial evidence) — 39 not found by the gene-target search above.

Carboplatin

Approved · 7 trials · source: ClinicalTrials.gov, Open Targets
NCT00214058 NCT00189553 NCT00989651

PaclitaxelNOT in gene-target list

Phase 3 · 7 trials · source: ClinicalTrials.gov, Open Targets
NCT00189553 NCT00989651 NCT06023862

Bevacizumab

Pre-approval · 5 trials · source: ClinicalTrials.gov, Open Targets
NCT06307249 NCT01091259 NCT00989651

Olaparib

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT05887609 NCT04532645 NCT03579316

Gemcitabine

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT04616534 NCT06023862 NCT07604766

Metformin

Phase 2 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT03792984 NCT00159536 NCT06015594

Cisplatin

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00989651 NCT00003896 NCT00006036

filgrastimNOT in gene-target list

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00004066 NCT00002977 NCT00467051

DocetaxelNOT in gene-target list

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00214058 NCT00004066

Letrozole

Phase 2/3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT06418347 NCT02389088

2X-121

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT03878849 NCT03878849

Pegylated liposomal doxorubicinNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00189553 NCT06023862

ChemotherapyNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02728622 NCT07033819

ZoladexNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01712893

quadratus lumborum blockNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06397300

lumbar epiduralNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06397300

Neoantigen polypeptide vaccineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06341907

ElimusertibNOT in gene-target list

Phase 1 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04616534

Bipolar coagulation forceps (ETHICON inc.)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03109964

SURGIFLO hemostatic matrix (ETHICON inc.)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03109964

Alpha lipoic acidNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06418347

SNPNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06307249

Palbociclib 125mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06307249

Vitamin B ComplexNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07191587

mirvetuximab soravtansine (MIRV; IMGN853)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04606914

Vitamin D3NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03792984

Calcium CarbonateNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03792984

Cinnamon Cap 500 MGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03778099

DoxilNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00945139

AvastinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00945139

Indication-extended Fertility-sparing TherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05945407

therapeutic autologous lymphocytesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00101257

Anthropometric and physical examinationNOT in gene-target list